Quintiles, Sinclair ink 10-year partnership to commercialize portfolio in Mexico
Wednesday, September 19, 2012
Quintiles, a fully integrated biopharmaceutical services company, and Sinclair IS Pharma, a topicals and supportive care specialist, have signed a 10-year collaboration and licensing agreement for Quintiles (Rowfarma Mexico) to commercialize Sinclair’s portfolio of dermo-cosmetic products and medical devices in Mexico.
Quintiles will handle the entire process including regulatory submissions; product importation, warehousing and distribution to wholesalers; sales force promotion to dermatologists and plastic surgeons; and marketing, advertising and promotion.
“This collaboration, a further step in Latin America, supports our company’s growth strategy: to move our product portfolio into fast-growing, emerging markets through strategic, regional partnerships,” said Chris Spooner, CEO of Sinclair IS Pharma. “Quintiles’ extensive commercialization experience and proven track record in Mexico and other emerging markets made it the clear choice to help us execute our strategy.”
The Sinclair portfolio includes: Atopiclair, for the treatment of mild to moderate atopic dermatitis; Kelo-cote silicone-gel scar reduction range, for the prevention and management of abnormal scars; Sebclair, for the treatment of seborrhoeic dermatitis; Bio-Taches, for hyperpigmentation disorders; XClair, for the treatment of radiation dermatitis; and Papulex, for the management and maintenance of mild to moderate acne.
“Our customers are thinking carefully about their strategy in emerging markets, and are looking for a trusted partner who can help navigate the complexities these markets present,” said James Featherstone, senior vice president of commercial strategy, Quintiles. “With this agreement, Quintiles will work on a wide range of services—from registration through to launch, to help Sinclair expand its geographic footprint in a more predictable manner.”